TREVI THERAPEUTICS INC
TRVINASDAQ🏆 #1503 by market capUS Equity
$934.92▲ $83.77 (+8.96%)
Simulated price1h—
24h▲ 9.0%
7d▲ 4918.4%
14d▲ 5073.9%
30d▲ 5562.7%
1y▲ 12646.0%
🏦Market Cap
$2.54B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
66
Fair
Trading Snapshot
- Day Range
- $922.69 – $953.14
- 52-Week Range
- $6.55 – $20.22
- Volume
- $2.53B
- Avg Volume
- $2.21B
- Shares Outstanding
- 142.0M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $403M
- Last Q Revenue
- $93M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.34
- Dividend Yield
- —
Why Investors Own TRVI
- ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$403M▲ +18.2% YoY
Gross Margin (TTM)
61.9%▲ +3.0% YoY
Operating Income (TTM)
$34M▲ +18.2% YoY
Free Cash Flow (TTM)
$37M▲ +18.2% YoY
About TREVI THERAPEUTICS INC
A company profile for TREVI THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
66/100
Analyst Price Target
ⓘAverage Target
$969.84
▲ +3.7% Upside
High Target$1,144.44
Low Target$800.98
Based on 18 analysts
Latest News & Updates
🚀
Barron’s·2h ago
TREVI THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift TRVI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
TREVI THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.